ABCSG 49 Overview

A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer

Study start : (global): 08/2019
(national): 10/2020
Coordinating Investigator: Balic, Marija; Graz
Patient Accrual: 400 (global), 50 (national)
Study Design:
(Click to enlarge)


Share on